Cybrexa Therapeutics picks up $25m Series B

Cybrexa Therapeutics, an oncology-focused biotechnology company, has closed $25 million in Series B financing.

Cybrexa Therapeutics, an oncology-focused biotechnology company, has closed $25 million in Series B financing. The investors included HighCape Capital and Elm Street Ventures.

Source: Press Release